Abstract
Introduction
Clinical and epidemiological reports have confirmed that cardiovascular disease is the major cause of death in w x diabetic patients 1,2 . The mechanisms behind the high incidence of diabetic cardiac dysfunction remain relatively obscure and may involve atherosclerosis or a combination of microangiopathy, macroangiopathy, autonomic neuropathy and other factors which produce structural, functional w x and biochemical alterations in the heart 3 . However, ( ) We have previously reported that Wistar rats made diabetic with STZ have a depressed cardiac function when w x compared to controls 10 . Remarkably, when Wistar-Kyoto Ž . WKY rats were administered the same dose of STZ, they did not develop the characteristic cardiomyopathy or dyslipidemia, despite being equally hyperglycemic and hypoinsulinemic as the Wistar strain at 12 weeks post-STZ w x 12 . It was thought that the preservation of normal cardiac function in diabetic WKY rats could be linked to the notable absence of hypertriglyceridemia in these animals. However, subsequent studies have failed to support this w x hypothesis 13 . It was thus considered possible that a strain-dependent susceptibility to STZ could explain the differences in cardiac function and triglyceride levels between Wistar and WKY diabetic rats. In support, relative to a rat strain of similar genetic background, the sponta-Ž . neously hypertensive rat SHR , the WKY rat was found to be less susceptible to the diabetogenic effects of either STZ or alloxan, with regard to plasma glucose, glycosyw x lated hemoglobin levels and heart rate 14,15 . Thus, in the present study, we questioned if both diabetic cardiomyopathy and hypertriglyceridemia could be induced in WKY rats by administering a higher dose of STZ.
Methods

Experimental animals
All the animals in the study were cared for in accordance with the principles promulgated by the Canadian Council on Animal Care and The University of British Ž . Columbia. Adult male Wistar-Kyoto WKY and Wistar Ž rats were obtained at 6-7 weeks of age Charles River . Canada, Montreal, Que. . The rats were maintained under Ž . a 12 h light 7.00-19.00 rdark cycle, and supplied with a Ž standard laboratory chow diet PMI Feeds, Richmond, . VA and water ad libitum.
Induction of diabetes
Wistar and WKY rats were randomly divided into non-diabetic and diabetic groups. Rats were administered Ž . halothane Ayerst Laboratories, Montreal, Que. anesthe-Ž sia, and diabetic rats injected with streptozotocin STZ, . Ž Sigma Chemical Co., St. Louis, MO at a moderate 55 . Ž . mgrkg or high 75 mgrkg dose into the tail vein, resulting in 4 diabetic groups: Wis55, Wis75, WKY55 and Ž WKY75. STZ was dissolved in saline NaCl, 154 mM, pH . 7.2 immediately before use. An equivalent volume of vehicle was administered to non-diabetic controls. Rats Ž . Ž . were housed 2 diabetic or 3 non-diabetic per cage. Glycosuria was determined at 24 h post-STZ via enzymatic test strips, and hyperglycemia was tested at 48 h using a Glucometer. All STZ-treated rats displayed both Ž . Ž . glycosuria ) 4 q and hyperglycemia ) 13 mM . Rats were kept for 6 weeks after STZ injection, at which time the rats were killed and heart and pancreas removed. 
Oral glucose tolerance test
Post-heparin plasma lipolytic actiÕity
The activity of LPL in post-heparin plasma was determined in control and diabetic rats, 5 weeks after diabetes induction. Heparin has been shown to displace LPL from Ž . its binding sites. Hence, heparin 0.5 Urg was injected into the tail vein of rats which were lightly anesthetized Ž . 20 mgrkg i.p. sodium pentobarbital and blood samples collected at 5 min. Plasma was separated by centrifugation for 10 min at 48C and stored at y708C until assayed for w x LPL activity 16 .
Lipase catalytic activity in plasma was determined by w 3 x measuring the in vitro hydrolysis of a sonicated H triolein substrate emulsion. The standard assay conditions w 3 x Ž were 0.6 mM glycerol tri 9,10-H oleate 1 mCirmmol; 1 . Ž . Ž . Ci s 37 GBq , 25 mM PIPES pH 7.5 , 0.05% wrv Ž . albumin, 50 mM MgCl , 2% vrv heat-inactivated 2 Ž chicken serum containing the LPL activator, apolipo-. protein CII , plus 5 ml of plasma sample in a total volume w 3 x of 400 ml. The release of H oleate was measured after an incubation of 30 min at 308C. The presence of hydrolyzed w 3 x H oleate in the medium was determined by adding 3 ml of a fatty acid extraction solution and 100 ml of 0.1 M w x NaOH 17 . After vortex mixing and centrifugation, the w 3 x Ž . radioactive sodium H oleate in a sample 0.5 ml of the upper phase was determined by liquid scintillation counting. All LPL assays were performed in duplicate under conditions where the reaction rate was linear with respect to time and the volume of plasma that was assayed. The validity of this assay for LPL activity has been previously w x w Ž . x established 17 . Total lipase hepatic HL q LPL activity was determined as follows. For the assay of HL, plasma was first incubated with 1 M NaCl and the assay per-Ž . formed in the absence of apolipoprotein CII Apo CII , to suppress LPL activity. Plasma LPL was calculated as the difference between total and hepatic lipase activity and is expressed in milliunits, which correspond to 1 nmol of fatty acid released per minute. 
Pancreatic insulin extraction
At termination, the pancreas was rapidly removed, cleared of lymph nodes and fat, blotted and weighed. The Ž . pancreas was immediately homogenized in 5 ml cold 2N Ž acetic acid for 5 s using a polytron homogenizer position . 5 , and then boiled for 10 min. The extract was centrifuged at 15 000 rpm for 10 min at 48C. The resulting supernatant was frozen in liquid nitrogen and stored at y708C until assayed for insulin.
Isolated working heart perfusion
Six weeks following STZ injection, heart function was determined using the isolated working heart preparation as w x described previously 18 . Rats were anesthetized with Ž . sodium pentobarbital 100 mgrkg, i.p. , the thoracic cavity opened and the heart removed. The hearts were placed in Ž . Ž . cold, aerated 95% O r5% CO Chenoweth-Koelle CK 2 2 Ž . buffer in mM : 120 NaCl, 5.6 KCl, 2.18 CaCl , 2.1 2 MgCl , 19.2 NaHCO , and 10 glucose. The aortic stump 2 3 was cannulated to a 15-gauge stainless steel perfusion cannula, and the heart was perfused retrogradely by the non-recirculating Langendorff technique with CK buffer. The perfusion fluid was continuously gassed with 95% O r5% CO in a double-walled water-heated chamber 2 2 maintained at 37 " 18C via a temperature-controlled circulating water bath. The pulmonary vein was cannulated via a 16-gauge stainless steel cannula connected to atrial fill-Ž . ing reservoirs. Left ventricular developed pressure LVDP was measured with a Statham P23 AA transducer attached to a 20-gauge needle inserted into the left ventricle. Cardiac work was initiated by switching the perfusion system from the retrograde to the working heart mode. Perfusate Ž from the peristaltic pump Masterflex, Cole-Parmer Instru-. ment Co., Chicago, IL, USA entered the left ventricle through the left atrium and was pumped out through the aortic stump. Following a 10-min equilibration period at a left atrial filling rate of 34 mlrmin, left ventricular function curves against various filling rates were recorded. The filling rate was first decreased stepwise from 34 to 30, 25 and 17 mlrmin, then increased stepwise to 25, 30, 34, 38, 42, 46, and 50 mlrmin. The pressures elicited in the left atrial cannula in response to these perfusion rates were 3.0, 4.7, 5.5, 6.3, 7.5, 9.0, 10 and 11 mmHg, respectively. The Ž aortic outflow was subjected to a constant afterload 150 . mmHg using PE160 tubing. Left ventricular pressure and the first derivative of left ventricular pressure were recorded on a Grass model 79D polygraph. Each heart was stimulated at twice the threshold voltage with square-wave pulses of 5 ms duration by placing a platinum electrode on the left atrium to give a rate of 275 beatsrmin. Cardiac w Ž . function data left ventricular developed pressure LVDP , Ž . rate of force development qdPrdt and rate of relaxation Ž . x y dPrdt were collected and analyzed as described prew x viously 18 .
Plasma measurements
Blood samples from the tail vein were collected in heparinized glass capillary tubes, and plasma stored at Ž . y208C. Plasma glucose and triglycerides TG were deter-Ž mined using diagnostic reagent kits Boehringer Mannheim . Canada, Laval, Que. . Plasma insulin was measured using Ž . rat insulin standards Novo, Copenhagen, Denmark . The radioimmunoassay method allows for measurement of small sample volumes of 25 ml, with an interassay and intra-assay coefficient of variation of less than 15% and a w x sensitivity to 10 mUrml 19 .
Materials
Joklik minimal essential medium was obtained from Ž . 
Statistical analysis
All data are reported as mean " s.e.m. One-or two-way Ž . analysis of variance ANOVA followed by the NewmanKeuls test was used to determine differences between group means using the Number Cruncher Statistical Sys-Ž . tem NCSS, Dr. Jerry L. Hintze, Kaysville, UT . Statistical significance was set at P -0.05. compared to WKY group at 55 mgrkg STZ. However, whereas both groups demonstrated similar degrees of glucose intolerance at 75 mgrkg STZ, glucose-stimulated insulin response in the Wis75 group was significantly Ž . lower than all other diabetic groups P -0.05 .
Results
Effect of STZ-diabetes on long-term cardiac function
Among the diabetic groups, significantly higher plasma triglyceride levels were only observed in Wistar rats ad-Ž . ministered high STZ Wis75 . This elevation in triglycerides was observed during both the fed and fasted states Ž . Table 1 . It should be noted that although not significantly different from control, plasma triglyceride levels in the 
Effect of STZ on pancreatic insulin content
Total pancreatic insulin content was significantly reduced in all of the diabetic groups to -10% of control Ž . Fig. 3 . There was a dose-dependent decrease in insulin content in both WKY and Wistar rats to STZ. WKY rats at both doses of STZ were found to have a significantly higher insulin content relative to the respective Wistar diabetic groups.
Effect of STZ on triglyceride clearance rate and LPL actiÕity
To determine the effect of STZ-diabetes on LPL-induced plasma triglyceride clearance, plasma LPL activity Ž and triglyceride levels were measured in the basal non-. fasted state and at 5 min after an i.v. heparin injection Ž . Fig. 4 . Heparin-releasable plasma LPL activity was significantly higher than control in Wis55, whereas it was Ž . significantly decreased in the Wis75 group Fig. 4A . Ž . Triglyceride clearance % reduction in 5 min in Wistar rats was decreased in a dose-dependent manner by STZ Ž . Fig. 4B . In contrast, induction of diabetes with either 55 or 75 mgrkg STZ in WKY rats had no effect on either Ž . heparin-releasable plasma LPL activity Fig. 4A or Ž . triglyceride clearance Fig. 4B . An association was found to exist between the levels of circulating triglycerides and plasma LPL activity in the basal, non-fasted state at 6 Ž . weeks after induction of diabetes Fig. 5 . Thus, in Wis75 rats, a sharp rise in plasma triglyceride levels coincided with a dramatically reduced basal LPL activity. Both WKY75 and Wis55 groups had similar basal LPL activities that were not as severely diminished as the Wis75 group, and both groups had plasma triglyceride levels which were similar to and not significantly different from control. Interestingly, non-diabetic WKY animals had a Fig. 5 . Association between the levels of circulating triglycerides and plasma LPL activity in the basal, non-fasted state at 6 weeks post-STZ. Basal plasma LPL activity was measured in the different groups before heparin injection. 
Discussion
STZ-induced diabetes in Wistar rats results in functional and structural abnormalities in the myocardium w x 8,20 . However, it was observed that when WKY rats were made diabetic with a similar dose of STZ, they did not develop the characteristic heart dysfunction at 12 w x weeks post-STZ 12 . We tested the possibility that a strain-dependent resistance to the diabetogenic effects of STZ could have contributed to the lack of cardiac dysfunction in the WKY rats. Administration of a moderate dose Ž . of STZ 55 mgrkg in the present study produced cardiac dysfunction in Wistar but not WKY rats at 6 weeks after diabetes induction. However, at this time point, the same dose of STZ in WKY rats also resulted in a lesser degree of hyperglycemia and glucose intolerance, and significantly higher pancreatic insulin content as compared to Wistar rats. Following a higher dose of STZ, WKY75 rats demonstrated an equal degree of hyperglycemia and glucose intolerance as Wis75 rats. In these animals, the apparent resistance towards the development of diabetesrelated cardiac dysfunction was also abolished. Hence, the absence of cardiomyopathy in WKY rats following a moderate dose of STZ may be the result of a less severe diabetes in these animals, which was overcome by administering a higher dose of the diabetogen. This observation suggests that strain differences in susceptibility to the diabetogenic effects of STZ may influence the onset and progression of diabetes-related complications such as cardiomyopathy. The factors contributing to strain differences in susceptibility to STZ-induced diabetes most probably involve cellular mechanisms which are under genetic conw x trol, such as b-cell defense and repair 21,22 . Thus, the sole analysis of plasma glucose levels in the fed state, as routinely done in many animal studies, may be insufficient in assessing the overall severity of the diabetic state, especially in the context of investigating the long-term complications of diabetes.
The etiology of diabetic cardiomyopathy is complex and a number of factors have been implicated in the pathogenic process. In the acute diabetic heart, metabolic derangements in both fuel supply and utilization by heart tissue could serve as the biochemical lesion initiating w x disease 23,24 . Human and animal studies have attempted to correlate myocardial changes during diabetes with changes in plasma lipids. In the Framingham and WHO studies, serum triglyceride levels were a strong risk factor w x for cardiovascular disease among diabetics 25,26 . Furthermore, in STZ-diabetic rats, treatments that lowered w x w x plasma lipids such as L-carnitine 27 and hydralazine 28 also prevented cardiac dysfunction. More recently, however, we have shown that several agents such as clofibrate, prazosin and enalapril, which produced triglyceride-lowering effects in STZ-diabetic rats, were ineffective in prew x serving myocardial function 13 . This lack of association between plasma lipid levels and cardiac function is further supported in the present study. Thus, despite triglyceride levels which were not significantly higher than control in either the WKY75 or Wis55 groups, heart function was severely diminished.
One interesting observation was that despite severe diabetes in WKY75 rats, plasma triglyceride levels were not adversely affected as in the Wis75 group. Hypertriglyceridemia characteristic of IDDM results from an w x increased secretion of VLDL-TG from the liver 29 , and a reduced clearance of TG-rich lipoproteins as a result of w x depressed LPL activity 30 andror compositional changes w x in circulating lipoproteins 31 . Since the breakdown of Ž . triglycerides in lipoproteins VLDL and chylomicrons is catalyzed by LPL, a rate-limiting enzyme, we examined whether the absence of hypertriglyceridemia in WKY75 rats could be secondary to the maintenance of normal LPL activity. Heparin-releasable plasma LPL activity or triglyceride clearance rates following i.v. heparin remained normal in WKY75 rats. Moreover, although basal plasma LPL activity was reduced in these animals, it appeared that significantly higher triglyceride levels were observed only when basal enzyme activity was diminished below a threshold level. Interestingly, we have recently observed that severe hypertriglyceridemia in SHR-diabetic rats was accompanied by a 4-fold reduction in basal plasma LPL activity, despite the presence of normal post-heparin plasma w x LPL activity 32 . These findings suggest that the absence of hypertriglyceridemia in WKY75 rats as compared to Wis75 could be associated with the maintenance of a critical basal LPL activity, although the post-heparin LPL pool may also play a significant role. As synthesis of LPL w x requires insulin 33 , the preservation of normal heparin-releasable LPL activity in a hypoinsulinemic milieu has yet to be understood.
In conclusion, the previously reported resistance of WKY rats to diabetes-induced cardiomyopathy after a moderate dose of STZ may be associated with a reduced susceptibility of this rat strain to the diabetogenic effects of STZ. Furthermore, it appears that the relative resistance of WKY rats to develop hypertriglyceridemia may be linked to the maintenance of a critical LPL pool. Finally, the appearance of cardiac dysfunction in the absence of pronounced hypertriglyceridemia in either Wistar rats given a moderate dose of STZ or in WKY rats administered a high STZ dose supports the notion that the cardiomyopathic condition is not dependent on prior exposure to high circulating triglyceride levels. 
